New Starters in the UK
Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Inés Dieringer and Joana Guedes.
UK Pricing and Reimbursement Market-System overview
Download the report to find out how pricing and reimbursement decisions are made in the UK, including, Payer Evaluation, Price setting and reimbursement
Promotions at Windrose, October 2024
Windrose are delighted to announce twelve promotions in our team.
New Starters in the UK, September 2024
Windrose Consulting Group are pleased to welcome the latest members of our team into the UK office; Jenny Marsh, Aashray Gupta, Jason King and Mar Casajuana.
New Starters in the US, September 2024
Windrose Consulting Group are delighted to welcome the latest members of our team into the US office; Ari Levin, Katharine K Yang, Jack Minigutti, Simon Rickman, Michelle Wang, Jasmine Line and Daniel Shapiro.
Q&As with our 2024 Summer interns at Windrose
In this Q&A, we are featuring our 2024 Summer Interns; Amol and Ushaan
Jose Galan joins Windrose as a Partner
Windrose Consulting Group are pleased to welcome our latest senior hire, Jose Galan, to our US office as a Partner.
Will SUSTAIN-HTA bring clarity to the pan-EU JCA methodologies and priorities?
With less than a year to go until the launch of the Joint Clinical Assessment (JCA) in January 2025, its successful implementation relies on the readiness of each EU market and their willingness to incorporate the JCA into current HTA processes.
CMS’s Cell and Gene Therapy (CGT) Access Model: Implications of Outcome-based Payment Models for Pharmaceuticals
The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder.
Florida to Import Canadian Prescription Drugs: Could this Transform US Healthcare?
On January 5th, 2024, the FDA allowed Florida the ability to import prescription drugs from Canada on a provisional basis.
Navigating the Impact of VPAG: Opportunities, Challenges, and Strategic Considerations for Pharmaceuticals
A new, non-contractual voluntary agreement has been implemented in the UK since the start of January 2024 and is set to run for 5 years, between the Department of Health and Social Care (DHSC)*, NHS England, and the Association of British Pharmaceutical Industry (ABPI).
Promotions at Windrose, April 2024
Windrose are delighted to announce four promotions in our team.
Registration is now open for the Cambridge Pricing and Market Access Course
Registration is now open for Developing a Successful Biopharmaceutical Pricing & Market Access Strategy, May - July 2024.
9 years of Windrose Consulting Group
Today, we are celebrating 9 years of Windrose Consulting Group!
New UK MHRA International Recognition Procedure set to streamline medicines applications post-Brexit
UK MHRA’s International Recognition Procedure (IRP) launch marks a key post-Brexit Health Technology Assessment (HTA) milestone, in an effort to speed up patient access to new medicines in the UK
Improving patient access to medicines - Affordability solutions as part of the puzzle
Affordability challenges can hinder patient access to medicines in many countries, especially those with low income or limited public health coverage. Thus, pharmaceutical companies are increasingly interested in exploring patient-targeted affordability solutions to widen access in the out-of-pocket (OOP) sector.
Impact of Denmark’s Recent Shift to Health Economic (HE) Evaluations and Its Evolution
In recent years, Denmark has shifted from its “added medical value” framework for evaluating new medicines and indication expansions in heath technology assessments (HTA) in favor of a quality-adjusted life year (QALY) approach, similar to that of NICE’s approach in the UK.
The Latin American and Caribbean Medicines Agency (AMLAC) may provide improved consistency in regulation, but what does that mean for access?
In April 2023, medical regulatory authorities of Colombia (INVIMA), Cuba (CECMED), and Mexico (COFEPRIS) signed the “Declaration of Acapulco” for the creation of the Latin American and Caribbean Medicines and Medical Devices Regulatory Agency (AMLAC)
Could 2024 Bring A Successful Spanish HTA Reform?
Despite changes to the IPT process in 2020, Spain continues to have a long and uncertain reimbursement process, where the average time to reimbursement is ~17 months. This article reviews the recent lawsuit against the Spanish MoH, and likely reforms for Spanish HTA processes in 2024.
Latest Promotions at Windrose
Kristina Funk and Adrian Jung have been promoted to Senior Analyst roles.